Global Blood Therapeutics, Inc.
GBTDelisted Oct 5, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted on Oct 5, 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.67B in total; Soros Fund Management was the only superinvestor holding it.
Holders of 5% or more of GBT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Global Blood Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Global Blood Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
22 Schedule 13D and 13G filings on Global Blood Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 14, 2023 | Deep Track Capital, LP | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jun 17, 2022 | Deep Track Capital, LP | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Baker Bros. Advisors LP | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13GOld format | – | – | – | SEC |
| Feb 3, 20224:41 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 31, 2022 | Bank of America Corp | 13G/AOld format | – | – | – | SEC |
| Oct 12, 2021 | Janus Henderson Group PLC | 13G/AOld format | – | – | – | SEC |
| May 13, 2021 | Point72 Asset Management, L.P. | 13GOld format | – | New | – | SEC |
| May 10, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Janus Henderson Group PLC | 13GOld format | – | New | – | SEC |
| Feb 10, 2021 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 8, 20215:14 PM ET | Bank of America Corp | 13G/AOld format | – | – | – | SEC |
| Feb 8, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jan 29, 20219:56 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Global Blood Therapeutics, Inc. shares.
No Form 144 notices for Global Blood Therapeutics, Inc. are on file.